Variation in Expression of Inflammation-Related Signaling Molecules with Profibrotic and Antifibrotic Effects in Cutaneous and Oral Mucosa Scars

Figure 2

TGFbeta1, TGFbeta2, TGFbeta3, and TNFalpha expression. (a) Cutaneous scar. Intense positivity of TGFbeta1 (2+) in mesenchymal and endothelial cells. TGFbeta1 x400. (b) Cutaneous scar. Very faint positivity of TGFbeta2 in multinucleated giant cells engulfing foreign material (suture); macrophages, mesenchymal, and endothelial cells are negative. TGFbeta2 x200. (c) Cutaneous scar. TGFbeta3 intense positivity in macrophages, multinucleated giant cells, mesenchymal, and endothelial cells. TGFbeta3 x400. (d). TGFbeta1 expression in mesenchymal cells in cutaneous scars related to scar age. (e). TGFbeta3 expression in mesenchymal cells in cutaneous scars related to localization. (f). Oral mucosa scar. Intense positivity of TGFbeta1 (2+) in mesenchymal, endothelial cells, and macrophages. Small island of odontogenic epithelium also positive. TGFbeta1 x200. (g) Oral mucosa scar. Negativity for TGFbeta2. The island of odontogenic epithelium also negative TGFbeta2 x200. (h). Oral mucosa scar. Intense positivity of TGFbeta3 (2+) in endothelial cells and macrophages. TGFbeta3 x400. (i) Oral mucosa scar. Intense positivity of TGFbeta3 (2+) in endothelial cells and faint positivity in macrophages and multinucleated giant cells. TGFbeta3 x400. (j). Cutaneous scar. Faint positivity of TNFalpha in macrophages and multinucleated giant cells; mesenchymal and endothelial cells are negative. TNFalpha x400. (k) TNFalpha expression in endothelial cells in cutaneous scars related to the scar age. (l) Oral mucosa scar. Negativity for TNFalpha. TNFalpha x200.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)